Language
Search
News
- Bruker and Lawrence Berkeley National Laboratory Collaborate on Novel Technology for Structural...
- Bruker Announces Four Ultra-High Field NMR Orders from the Central European Institute of Technology...
- CMC-assist™, the First NMR Software Tool Enabling the Seamless, Integrated Routine Workflow from...
- MR Newsletter 08/2011
Stroke
Cerebroprotective Drug Trials
Courtesy of M. Eis, M. Neumaier, U. Pschorn
Boehringer Ingelheim Pharma KG, Dept CNS Research, Ingelheim, Germany
- These data were acquired using a BioSpec 47/40
Rat brains at three time-points after an MCAO* insult, with (bottom row) and without (top row) cerebroprotective drug treatment. The compound reduces the growth of both lesion volume and its severity (note the very different lesion size at the outset).
*MCAO: Middle Cerebral Artery Occlusion
